20 September 2023>: Clinical Research
Early Echocardiography and ECG Changes Following Radiotherapy in Patients with Stage II–III HER2-Positive Breast Cancer Treated with Anthracycline-Based Chemotherapy with or without Trastuzumab-Based Therapy
Radu Valeriu Toma 12ABCG , Zgura Anca 1E , Oana Gabriela Trifănescu 12A , Laurenţia Nicoleta Galeş 12D* , Antonia Ruxandra Folea 2CDEF , Loredana Stanca 3B , Liviu Bîlteanu 234ABCDEF* , Rodica M. Anghel 1ADOI: 10.12659/MSM.941754
Med Sci Monit 2023; 29:e941754
Supplementary Table 12 Parameter estimates of in multinomial logistic models including the predictors in Figure 3 in the manuscript for EF drop continuation after CHT.
B | Std. error | Wald | df | Sig. | Exp(B) | 95% confidence interval for Exp(B) | |||
---|---|---|---|---|---|---|---|---|---|
Lower bound | Upper bound | ||||||||
Model 1 | Intercept | −5.622 | 2.176 | 6.675 | 1 | .010 | |||
[Pre-existing] cardiac diseases | 3.083 | 1.340 | 5.293 | 1 | .021 | 21.816 | 1.578 | 301.536 | |
LAD Mean Dose ≥32.7 Gy | 2.657 | 1.294 | 4.212 | 1 | .040 | 14.248 | 1.127 | 180.107 | |
Model 2 | Intercept | −4.830 | 1.540 | 9.838 | 1 | .002 | |||
[Pre-existing] cardiac diseases | 3.061 | 1.006 | 9.255 | 1 | .002 | 21.346 | 2.971 | 153.369 | |
Cycle 3 dose ≥160 mg/m | 2.144 | .891 | 5.784 | 1 | .016 | 8.533 | 1.487 | 48.966 |